Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin
- PMID: 12087008
- DOI: 10.2337/diacare.25.7.1123
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin
Erratum in
- Diabetes Care. 2002 Sep;25(9):1671.
Abstract
Objective: The purpose of this study was to assess the effect of orlistat, a gastrointestinal lipase inhibitor, on body weight, glycemic control, and cardiovascular risk factors in metformin-treated type 2 diabetic patients.
Research design and methods: A 1-year multicenter, randomized, double-blind, placebo-controlled trial of 120 mg orlistat t.i.d. (n = 249) or placebo (n = 254) combined with a reduced-calorie diet was conducted in overweight and obese patients with suboptimal control of type 2 diabetes.
Results: After 1 year of treatment, mean (+/-SE) weight loss was greater in the orlistat than in the placebo group (-4.6 +/- 0.3% vs. -1.7 +/- 0.3% of baseline wt, P < 0.001). Orlistat treatment caused a greater improvement in glycemic control than placebo, as evidenced by a greater reduction in serum HbA(1c), adjusted for changes in metformin and sulfonylurea therapy (-0.90 +/- 0.08 vs. -0.61 +/- 0.08, P = 0.014); a greater proportion of patients achieving decreases in HbA(1c) of > or = 0.5 and > or = 1.0% (both P < 0.01); and a greater reduction in fasting serum glucose (-2.0 +/- 0.2 vs. -0.7 +/- 0.2 mmol/l, P = 0.001). Compared with the placebo group, patients treated with orlistat also had greater decreases in total cholesterol, LDL cholesterol, and systolic blood pressure (all P < 0.05). Although more subjects treated with orlistat experienced gastrointestinal side effects than placebo (83 vs. 62%, P < 0.05), more subjects in the placebo group withdrew prematurely from the study than in the orlistat group (44 vs. 35%, P < 0.05).
Conclusions: Orlistat is a useful adjunctive treatment for producing weight loss and improving glycemic control, serum lipid levels, and blood pressure in obese patients with type 2 diabetes who are being treated with metformin.
Similar articles
-
Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.Diabetes Care. 2002 Jun;25(6):1033-41. doi: 10.2337/diacare.25.6.1033. Diabetes Care. 2002. PMID: 12032111 Clinical Trial.
-
Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.Diabetes Care. 1998 Aug;21(8):1288-94. doi: 10.2337/diacare.21.8.1288. Diabetes Care. 1998. PMID: 9702435 Clinical Trial.
-
A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin.Diabet Med. 2005 May;22(5):612-8. doi: 10.1111/j.1464-5491.2004.01474.x. Diabet Med. 2005. PMID: 15842517 Clinical Trial.
-
Obesity medications and the treatment of type 2 diabetes.Diabetes Technol Ther. 1999 Fall;1(3):277-87. doi: 10.1089/152091599317198. Diabetes Technol Ther. 1999. PMID: 11475274 Review.
-
New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.Diabetes Metab. 2002 Dec;28(6 Pt 1):437-45. Diabetes Metab. 2002. PMID: 12522323 Review.
Cited by
-
Weight considerations in pharmacotherapy for type 2 diabetes.J Obes. 2011;2011:984245. doi: 10.1155/2011/984245. Epub 2010 Sep 19. J Obes. 2011. PMID: 20885921 Free PMC article.
-
Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis.Diabetes Metab Syndr Obes. 2022 Dec 17;15:3961-3987. doi: 10.2147/DMSO.S392952. eCollection 2022. Diabetes Metab Syndr Obes. 2022. PMID: 36569429 Free PMC article. Review.
-
Orlistat: a review of its use in the management of obesity.Drugs. 2006;66(12):1625-56. doi: 10.2165/00003495-200666120-00012. Drugs. 2006. PMID: 16956313 Review.
-
Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications.Hypertens Res. 2012 Jan;35(1):4-16. doi: 10.1038/hr.2011.173. Epub 2011 Nov 3. Hypertens Res. 2012. PMID: 22048570 Free PMC article. Review.
-
2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association.Diabetes Metab J. 2025 Jul;49(4):582-783. doi: 10.4093/dmj.2025.0469. Epub 2025 Jul 1. Diabetes Metab J. 2025. PMID: 40631460 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous